Health Industry News
VIVA! Communications clinches gold & two silvers at Public Relations Institute of Australia Golden Target Awards
Team VIVA! was dressed to impress at the annual PRIA Golden Target Awards (GTAs) held at the Sofitel Darling Harbour, Sydney, last night (Thursday, December 1, 2022). A show-stopping 146 finalists representing 35 categories assembled for Australia’s longest-running, and most prestigious public relations and communications awards that both celebrate, and recognise, individuals, agencies and campaigns demonstrating strategic…
Read MoreVIVA! Communications clinches Best PR Campaign – Awareness and Advocacy with Edwards Lifesciences at the 2022 PRIME Awards
VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma, and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel. Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…
Read More
First treatment in 10 years PBS listed for Aussies
living with aggressive stomach & oesophageal cancers
Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…
Read More9 in 10 Australians with deadly heart valve disease not undergoing treatment
Non-surgical treatment now available on Medicare Of the estimated 66,500 Australians living with aortic stenosis, 9 in 10 are not undergoing treatment each year for the potentially life-threatening disease. However, the inclusion of transcatheter aortic valve implantation (TAVI) on Medicare from July 1, 2022, is expanding access to the minimally invasive treatment option for all…
Read MoreAussie men with advanced prostate cancer denied access to innovative treatment on Medicare
Almost 20,000 Australian men diagnosed each year with prostate cancer are being denied access to an innovative treatment on Medicare for the nation’s most common cancer in men. Two treatment options – low dose rate brachytherapy (LDR-brachytherapy) and external beam radiation therapy – are approved to treat prostate cancer in Australia by the medical regulator,…
Read More